REG - Derwent London PLC - City Road Island EC1 Exchange of Contract

Derwent LondonAnnouncement

05/05/2022 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220505:nRSE3675Ka&default-theme=true

RNS Number : 3675K  Derwent London PLC  05 May 2022

 

5 May 2022

Derwent London plc ("Derwent London" / "the Group")
Exchange of conditional contract to acquire City Road Island EC1

 

Derwent London is pleased to announce that it has exchanged a conditional
contract to acquire the freehold of City Road Island EC1, the site of the
Moorfields Eye Hospital and the UCL Institute of Ophthalmology.

The site is being sold by Moorfields Eye Hospital NHS Foundation Trust and
UCL, together the Oriel joint initiative ("Oriel"), for £239m(1) before
costs. This is subject to receipt of final Treasury approval, which is
expected in H2 2022. Completion is also conditional on delivery by Oriel of
the new eye hospital at St Pancras and subsequent vacant possession of City
Road Island which is anticipated in early 2027.

Derwent London has appointed architects AHMM alongside a full professional
team and will undertake significant community engagement as part of its
regeneration plans. This important 2.5 acre site, with its c.400,000 sq ft of
existing buildings, is located in the heart of the Tech Belt where the Group
has substantial holdings. Our early appraisals show the site has potential to
deliver a major 750,000+ sq ft campus with generous public realm and strong
environmental credentials.

Paul Williams, Chief Executive of Derwent London, said:

"We are delighted to have secured such an important central London
regeneration opportunity in the heart of the Tech Belt, where we aim to
deliver the next generation of distinctive 'long-life, loose-fit, low carbon'
commercial space."

Martin Kuper, Chief Executive of Moorfields Eye Hospital NHS Foundation Trust
said:

"This is an important step forward for our plans for Oriel, a new eye care,
research and education centre. The sale of our City Road Island, which is
conditional on Treasury approval of Oriel, is a key element of our funding
strategy. All proceeds will be reinvested in the new centre to secure the
long-term future of world-leading eye care, research and education in a way
that represents value for money and benefits our patients. We will continue to
maintain our strong links with Islington Council as plans for City Road Island
progress."

Professor Alan Thompson, Dean of the UCL Faculty of Brain Sciences, said:

"This is a significant step towards realising the Oriel joint initiative.
Oriel will bring together UCL's formidable research base with Moorfields'
world-class healthcare delivery in one integrated centre of research,
education and care."

Robert Dufton, Chief Executive, Moorfields Eye Charity, said:

"We're very pleased to reach this significant milestone in achieving Oriel
which helps to secure investment in the new world-leading centre for eye
health integrating research, patient care and education in a state-of-the-art
building and benefitting people on a global scale. Philanthropy has a critical
role to play in realising Oriel. We're very grateful to donors who have
committed their support and to those interested in hearing more."

Initial impact on earnings and NAV

Derwent London is disclosing the following additional information for Listing
Rules purposes.

On completion the acquisition is expected to have a marginal impact on the
Group's earnings.

The £239m(1) consideration to be paid by the Group on completion of the
acquisition is in line with the market valuation for the estate which does not
yet benefit from planning consent and will be paid from undrawn debt
facilities and cash.  The contract also contains potential overage
arrangements that may be payable based on the planning consent that is
achieved and/or any future disposal of the site within an agreed time period.
The potential amounts payable in relation to such overage arrangements are
subject to an aggregate cap, with such cap also including the purchase
consideration to be paid on completion.

(1) The exact amount depends on the terms of the planning consent obtained as
at the point of completion of the acquisition, with

  £239m being the base consideration.

 

 

 

 

 

 

For further information, please contact:

 

 Derwent London             Paul Williams, Chief Executive

 Tel: +44 (0)20 7659 3000   Nigel George, Executive Director

                            Robert Duncan, Head of Investor Relations

 Brunswick Group            Nina Coad

 Tel: +44 (0)20 7404 5959   Emily Trapnell

 

 

Notes to editors

 

Derwent London plc

 

Derwent London plc owns 77 buildings in a commercial real estate portfolio
predominantly in central London valued at £5.7 billion as at 31 December
2021, making it the largest London-focused real estate investment trust
(REIT).

 

Our experienced team has a long track record of creating value throughout the
property cycle by regenerating our buildings via development or refurbishment,
effective asset management and capital recycling.

 

We typically acquire central London properties off-market with low capital
values and modest rents in improving locations, most of which are either in
the West End or the Tech Belt.  We capitalise on the unique qualities of each
of our properties - taking a fresh approach to the regeneration of every
building with a focus on anticipating tenant requirements and an emphasis on
design.

 

Reflecting and supporting our long-term success, the business has a strong
balance sheet with modest leverage, a robust income stream and flexible
financing.

 

As part of our commitment to lead the industry in mitigating climate change,
Derwent London has committed to becoming a net zero carbon business by 2030,
publishing its pathway to achieving this goal in July 2020.  In 2019 the
Group became the first UK REIT to sign a Revolving Credit Facility with a
'green' tranche.  At the same time, we also launched our Green Finance
Framework and signed the Better Buildings Partnership's climate change
commitment.  The Group is a member of the 'RE100' which recognises Derwent
London as an influential company, committed to 100% renewable power by
purchasing renewable energy, a key step in becoming a net zero carbon
business.  Derwent London is one of only a few property companies worldwide
to have science-based carbon targets validated by the Science Based Targets
initiative (SBTi).

 

Landmark buildings in our 5.6 million sq ft portfolio include 80 Charlotte
Street W1, Brunel Building W2, White Collar Factory EC1, Angel Building EC1,
1-2 Stephen Street W1, Horseferry House SW1 and Tea Building E1.

 

In January 2022 we were proud to announce that we had achieved the National
Equality Standard - the UK's highest benchmark for equality, diversity and
inclusion.  In April 2022, Derwent London won the BCO Best Commercial
Workplace award for 80 Charlotte Street.  In October 2021, the Group won EG's
UK Company of the Year award and in January 2022 came top of the Property
Sector and 38th position overall in Management Today's Britain's Most Admired
Companies awards 2021.  In 2020 the Group won several awards for Brunel
Building with the most prominent being the BCO Best Commercial Workplace
award.  In 2019 the Group won EG Offices Company of the Year, the CoStar West
End Deal of the Year for Brunel Building and Westminster Business Council's
Best Achievement in Sustainability award.  In 2013 the Company launched a
voluntary Community Fund and has to date supported well over 100 community
projects in the West End and the Tech Belt.

 

The Company is a public limited company, which is listed on the London Stock
Exchange and incorporated and domiciled in the UK.  The address of its
registered office is 25 Savile Row, London, W1S 2ER.

 

For further information see www.derwentlondon.com
(http://www.derwentlondon.com) or follow us on Twitter at @derwentlondon

 

Forward-looking statements

This document contains certain forward-looking statements about the future
outlook of Derwent London.  By their nature, any statements about future
outlook involve risk and uncertainty because they relate to events and depend
on circumstances that may or may not occur in the future.  Actual results,
performance or outcomes may differ materially from any results, performance or
outcomes expressed or implied by such forward-looking statements.

No representation or warranty is given in relation to any forward-looking
statements made by Derwent London, including as to their completeness or
accuracy.  Derwent London does not undertake to update any forward-looking
statements whether as a result of new information, future events or
otherwise.  Nothing in this announcement should be construed as a profit
forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQEAXSLEAAAEFA